The present invention provides acyl sulfonamide compounds of general formula (I):

##STR00001## in which X, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6′ R.sup.a and R.sup.b are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients as well as methods of treating and/or prophylaxing diseases, particularly cancer, more particularly cancer in which KAT6A and/or KAT6B is focally amplified, said method comprising administering an effective amount of at least one compound of formula (I) to a subject in need thereof.

This invention relates to a composition comprising benzoic acid, derivatives or metabolites thereof, optionally in combination with a mixture of at least one essential oil compounds selected from the group consisting of thymol, eugenol and piperine, for improving growth performance of an animal subjected to coccidiosis vaccine challenge, and use thereof.

This invention relates to a composition comprising benzoic acid, derivatives or metabolites thereof, optionally in combination with a mixture of at least one essential oil compounds selected from the group consisting of thymol, eugenol and piperine, for improving growth performance of an animal subjected to coccidiosis vaccine challenge, and use thereof.

The present invention relates to the use of a combination of a phosphodiesterase 4 (PDE4) inhibitor and one or more of 5-HT.sub.4 agonist, an H.sub.3 antagonist or inverse agonist, a nicotinic α.sub.7 receptor agonist, a β.sub.3 adrenergic agonist or a TAAR1 agonist for the treatment of psychiatric or neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction exists (such as major depressive disorder, bipolar I disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative and cognitive symptoms), as well as Parkinson's disease (e.g. non-motor features such as depression, apathy and cognitive impairment)).

The present invention relates to the use of a combination of a phosphodiesterase 4 (PDE4) inhibitor and one or more of 5-HT.sub.4 agonist, an H.sub.3 antagonist or inverse agonist, a nicotinic α.sub.7 receptor agonist, a β.sub.3 adrenergic agonist or a TAAR1 agonist for the treatment of psychiatric or neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction exists (such as major depressive disorder, bipolar I disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative and cognitive symptoms), as well as Parkinson's disease (e.g. non-motor features such as depression, apathy and cognitive impairment)).

The present invention provides methods for alleviating menopausal symptoms as a result of chemotherapy-induced or natural menopause in a subject, the method comprising administering an effective amount of a natural product or combination of natural products tailored to a subjects specific symptoms, with an effective amount of hormonal or non-hormonal synthetic prescription medication. In particular embodiments, the natural product or combination of natural products alleviate vasomotor menopausal symptoms in a subject, while the prescription medication alleviates symptoms associated with genitourinary syndrome of menopause. In some embodiments, the natural product or combination of natural products is prepared in formulations designed for administration at different times of day.

The present invention provides methods for alleviating menopausal symptoms as a result of chemotherapy-induced or natural menopause in a subject, the method comprising administering an effective amount of a natural product or combination of natural products tailored to a subjects specific symptoms, with an effective amount of hormonal or non-hormonal synthetic prescription medication. In particular embodiments, the natural product or combination of natural products alleviate vasomotor menopausal symptoms in a subject, while the prescription medication alleviates symptoms associated with genitourinary syndrome of menopause. In some embodiments, the natural product or combination of natural products is prepared in formulations designed for administration at different times of day.

A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

A composition for preventing and/or treating pancreatitis and a method of prevention and/or treatment of pancreatitis are disclosed. The composition include an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof.

The present invention provides a dosage regimen for safe and efficacious administration of esketamine and rapid-acting antidepressants in the treatment of major depressive disorder (MDD).